Gain Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-20.2M | $-20.4M | $-22.3M | $-17.6M | $-13.9M | $-3.6M |
| Depreciation & Amortization | $94.0K | $84.1K | $83.6K | $64.2K | $15.5K | $9.6K |
| Depreciation | $45.0K | $38.0K | $35.0K | $26.6K | $15.5K | $9.6K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $1.8M | $2.4M | $3.3M | $1.5M | $839.4K | $81.6K |
| Net Cash from Operating Activities | $-18.5M | $-18.9M | $-18.9M | $-14.7M | $-12.4M | $-3.2M |
| Investing Activities | ||||||
| Capital Expenditures | — | $22.5K | $15.4K | $119.0K | $94.2K | $20.8K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $5.0M | $10.2M | $-14.8M | $-94.2K | $-20.8K |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $28.4M | $13.0M | $12.6M | $-78.8K | $41.8M | $10.5M |
| Net Change in Cash | $10.5M | $-1.4M | $4.5M | $-29.6M | $29.4M | $7.2M |
| Free Cash Flow | — | $-18.9M | $-18.9M | $-14.8M | $-12.5M | $-3.3M |